Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint Blockade for Advanced Melanoma
Findings from a multicentre cohort study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer
Conversion to traditional approval is based on an additional patients and an added follow-up time to assess duration of response in the VISION study
Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic NSCLC Following Prior Failure to Anti-PD1/PD-L1 and Platinum-Doublet Therapy
Findings from the HUDSON study
A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with Prolonged OS After First-Line Treatment with Panitumumab plus Chemotherapy in Patients with RAS wt mCRC
Findings from an exploratory preplanned biomarker analysis of the PARADIGM study
FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Evidence for efficacy is based on the results from the NAPOLI 3 study
An Increase in Healthcare Costs Associated with the Use of Multigene Panel Testing for the Treatment of Patients with Advanced Cancer
Findings from the OCTANE analysis
Final OS and the Exploratory Analysis of the Outcome with Osimertinib Up-Front versus the Sequential Approach in Patients with Advanced EGFR-mutated NSCLC
Findings from the EORTC LCG-163 APPLE study
EMA Recommends Granting Marketing Authorisation for Efbemalenograstim Alfa
It is intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy
Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor, in Allcomers Solid Tumours
Findings from a dose-escalation phase I study
Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should Be Based on Anatomy, CA 19-9, and Performance Status
Findings from the Trans-Atlantic Pancreatic Surgery Consortium study
A New Online Tool Predicts RFS and OS Probabilities in Patients with Stage II Melanoma
MIA calculator should help inform clinicians on which patients to select for adjuvant therapy
EMA Recommends Extension of Indications for Idecabtagene Vicleucel
It concerns the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies